SAWAI GROUP HOLDINGS Co., Ltd. Logo

SAWAI GROUP HOLDINGS Co., Ltd.

A leading Japanese generic drug maker expanding into digital health and wellness solutions.

4887 | T

Overview

Corporate Details

ISIN(s):
JP3323040000
LEI:
Country:
Japan
Address:
大阪市淀川区宮原5丁目2−30
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sawai Group Holdings Co., Ltd. is a holding company primarily engaged in the pharmaceutical business. Its core subsidiary, Sawai Pharmaceutical Co., Ltd., is a leading Japanese manufacturer of generic drugs, focusing on the research, development, production, and sale of high-quality, affordable medications across various therapeutic areas, including treatments for hypertension and dyslipidemia. The Group aims to contribute to reducing patient financial burdens and supporting sustainable healthcare systems. In addition to its core generics business, the company is expanding into the broader healthcare field, including digital health solutions and wellness services through subsidiaries such as FrontAct, which develops treatment support apps and provides health monitoring devices. The Group's mission is to support healthier lives for people worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-31 03:04
Registration Form
訂正発行登録書
Japanese 24.2 KB
2025-06-27 02:47
Regulatory News Service
訂正発行登録書
Japanese 10.0 KB
2025-06-26 07:49
Post-Annual General Meeting Information
臨時報告書
Japanese 31.2 KB
2025-06-24 08:06
Governance Information
内部統制報告書-第4期(2024/04/01-2025/03/31)
Japanese 24.3 KB
2025-06-24 08:06
Registration Form
確認書
Japanese 9.0 KB
2025-06-24 08:05
Annual Report
有価証券報告書-第4期(2024/04/01-2025/03/31)
Japanese 2.0 MB
2025-05-27 05:40
Registration Form
訂正発行登録書
Japanese 9.6 KB
2025-05-27 02:50
Regulatory News Service
臨時報告書
Japanese 20.1 KB
2025-04-03 06:28
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.4 KB
2025-03-05 07:02
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 27.8 KB
2025-02-05 07:08
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.2 KB
2025-01-08 07:53
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 27.7 KB
2024-12-04 07:05
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.5 KB
2024-11-11 07:47
Interim Report
確認書
Japanese 9.1 KB
2024-11-11 07:46
Interim Report
半期報告書-第4期(2024/04/01-2025/03/31)
Japanese 350.6 KB

Automate Your Workflow. Get a real-time feed of all SAWAI GROUP HOLDINGS Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SAWAI GROUP HOLDINGS Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SAWAI GROUP HOLDINGS Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Imunon, Inc. Logo
Developing DNA-based immunotherapies for oncology and infectious diseases.
United States of America
IMNN
IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America
INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom
INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX

Talk to a Data Expert

Have a question? We'll get back to you promptly.